| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAGEA4 |
| Uniprot No | P43358 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-317aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMSSEQKSQHCKPEEGVEAQEEALGLVGAQA PTTEEQEAAVSSSSPLVPGTLEEVPAAESAGPPQSPQGASALPTTISFTC WRQPNEGSSSQEEEGPSTSPDAESLFREALSNKVDELAHFLLRKYRAKEL VTKAEMLERVIKNYKRCFPVIFGKASESLKMIFGIDVKEVDPTSNTYTLV TCLGLSYDGLLGNNQIFPKTGLLIIVLGTIAMEGDSASEEEIWEELGVMG VYDGREHTVYGEPRKLLTQDWVQENYLEYRQVPGSNPARYEFLWGPRALA ETSYVKVLEHVVRVNARVRIAYPSLREAALLEEEEGV |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
nan
**Background of MAGEA4 Recombinant Protein**
The **MAGEA4** (Melanoma-Associated Antigen A4) protein is a member of the MAGE (Melanoma Antigen Gene) family, a group of proteins initially identified for their restricted expression in normal tissues and overexpression in various cancers. MAGE proteins belong to the broader category of cancer-testis antigens (CTAs), which are typically expressed in germline cells but re-emerge in malignancies, making them attractive targets for immunotherapy. MAGEA4. located on the X chromosome (Xq28), shares structural homology with other MAGE-A family members, including a conserved **MAGE homology domain (MHD)** involved in protein-protein interactions and regulatory functions.
Recombinant MAGEA4 is engineered using biotechnological methods, such as expression in bacterial or mammalian systems, to produce purified protein for research and therapeutic applications. Its recombinant form retains immunogenic epitopes, enabling studies on antigen-specific immune responses. MAGEA4 is implicated in tumorigenesis through roles in transcriptional regulation, apoptosis evasion, and cell cycle progression, though its precise mechanisms remain under investigation.
Clinically, MAGEA4 is prioritized as a target for cancer vaccines, adoptive T-cell therapies (e.g., CAR-T), and checkpoint inhibitors due to its tumor-specific expression. However, challenges persist, including potential off-target effects linked to low MAGEA4 expression in some normal tissues (e.g., placenta) and heterogeneity across cancer types. Additionally, recombinant MAGEA4 serves as a tool for antibody development, biomarker validation, and screening small molecules aimed at disrupting its oncogenic interactions.
Research continues to explore MAGEA4’s role in immune evasion and its interplay with pathways like p53 and Wnt signaling. Despite progress, understanding its functional diversity across cancers and improving targeted delivery remain critical for advancing MAGEA4-based therapies.
×
